Claudin18.2 Targeted Therapies: A Complete Guide to Drugs and Clinical Trials for Gastric and Pancreatic Cancer (2026)
Claudin18.2 — a tight junction protein normally found in stomach lining — has emerged as one of the most promising targets in oncology. When tumors overexpress this protein, it becomes an ideal surface marker for precision therapies: CAR-T cells, antibody-drug conjugates (ADCs), monoclonal antibodies, and bispecific antibodies.
As of mid-2026, over 100 clinical trials are registered globally targeting Claudin18.2, with Chinese biotech companies leading the development pipeline. The flagship product — CT041, a CAR-T therapy — is under NMPA review and could become the first CAR-T therapy approved for a solid tumor anywhere in the world.
Here’s what international patients need to know about this rapidly evolving landscape.
Important: This article is for informational purposes only and does not constitute medical advice. Always consult with your treating oncologist before making any treatment decisions.
The Key Update: What Changed in 2026
| Area | Status |
|---|---|
| CT041 (CAR-T) | NDA under NMPA review — expected approval H1 2026, but no announcement yet as of April 2026 |
| Zolbetuximab | Approved and commercially available (self-pay in China, ~¥5,978 per 100mg vial). NOT in 2026 national medical insurance catalog |
| IBI343 (ADC) | Phase III recruiting; 2 new Phase II trials launched March 2026 |
| LM-302 (ADC) | Phase III enrollment complete — first Claudin18.2 ADC to finish Phase III enrollment globally |
| ASCO 2026 | New ADC data emerging: XNW27011, TQB2103, IMC002 (CAR-T, ORR 66.7%) |
How Claudin18.2 Therapies Work
Claudin18.2 is a protein that controls what passes between cells in the stomach lining. In healthy tissue, it’s hidden deep within tight junctions — invisible to the immune system. But in certain cancers (gastric, gastroesophageal junction, and pancreatic), the protein becomes exposed on the tumor cell surface, making it a target.
Four therapeutic approaches are being developed:
1. CAR-T Cell Therapy — Patient’s T-cells are genetically engineered to recognize Claudin18.2 on tumor cells. Most potent but most complex.
2. Monoclonal Antibodies — Lab-made antibodies that bind to Claudin18.2 and flag cancer cells for immune destruction. Zolbetuximab is the first approved example.
3. Antibody-Drug Conjugates (ADCs) — An antibody that delivers chemotherapy directly to Claudin18.2-expressing cells, minimizing systemic toxicity. This is the fastest-growing category.
4. Bispecific Antibodies — Engineered to bind both Claudin18.2 and immune cells (like T-cells), bringing them into proximity for killing.
The Major Drugs: Status and Efficacy
Tier 1: Approved or Near-Approval
| Drug | Company | Type | Status | Key Data |
|---|---|---|---|---|
| Zolbetuximab | Astellas | Monoclonal Ab | ✅ Approved (not in China insurance) | LUCERNA III期: mPFS 18.0mo (high expression) |
| CT041 | CARsgen | CAR-T | ⚠️ NDA under review | ORR 61.1%, DCR 91.8% (gastric/GEJ) |
Zolbetuximab is the first Claudin18.2-targeting drug to receive regulatory approval globally. However, it’s not covered by China’s national medical insurance — patients pay approximately ¥5,978 per 100mg vial, making annual treatment costs substantial.
CT041 is the most-watched product in the pipeline. If approved, it would be the first CAR-T therapy for any solid tumor worldwide. CARsgen’s March 2026 earnings report indicated expected H1 2026 approval, but no formal NMPA announcement has been made as of late April.
Tier 2: Phase III Trials
| Drug | Company | Type | Phase | Key Data |
|---|---|---|---|---|
| IBI343 | Innovent | ADC | III期 (recruiting) | Pancreatic: cDCR 81.4%, cORR 23.3%, mPFS 5.3mo |
| LM-302 | LaNova | ADC | III期 (enrollment complete) | +PD-1: ORR 65.9%, DCR 85.4% |
| CMG901 | Kymab/AZ | ADC | III期 (recruiting) | ORR 29–35%, mOS 11.8mo |
| SHR-A1904 | Hengrui | ADC | III期 (recruiting) | Data pending |
Tier 3: Phase II with Promising Signals
| Drug | Company | Type | Key Data |
|---|---|---|---|
| RC118 | RemeGen | ADC | Combined ORR 52.4% |
| ATG-022 | Antengene | ADC | ORR 46.7% (1.8mg/kg) |
| FG-M108 | MingJi Bio | Monoclonal Ab | IRC-ORR 53.1%, DCR 100% (pancreatic, 1L) |
| IMC002 | Yimai Bio | CAR-T | ORR 66.7%, sustained CR 60 weeks |
| QLS31905 | Qilu Pharma | Bispecific | FDA Orphan Drug (March 2026) |
Efficacy Comparison: What the Numbers Show
| Drug | Type | Cancer Type | Line | ORR | DCR | mPFS | mOS |
|---|---|---|---|---|---|---|---|
| CT041 | CAR-T | Gastric/GEJ | 2L+ | 61.1% | 91.8% | NR | NR |
| Zolbetuximab + triplet | Ab | Gastric/GEJ | 1L | 68.1% | — | 18.0mo | — |
| JS107 + triplet | ADC | Gastric/GEJ | 1L | ~86.7%* | 100% | 11.14mo | — |
| LM-302 + PD-1 | ADC | Gastric/GEJ | 3L+ | 65.9% | 85.4% | NR | NR |
| IBI343 | ADC | Pancreatic | 2L+ | 23.3% | 81.4% | 5.3mo | 9.1mo |
| CMG901 | ADC | Gastric/GEJ | 2L+ | 29–35% | 65–70% | 4.8mo | 11.8mo |
| FG-M108 | Ab | Pancreatic | 1L | 53.1% | 100% | 9.9mo | — |
*JS107 ORR data has conflicting reports (80% vs 86.7%). The 86.7% figure from ESMO Asia 2025 is likely the most recent.
Key takeaways:
- CT041 shows the strongest efficacy signals (ORR 61.1%, DCR 91.8%) but is CAR-T — complex manufacturing, limited availability
- Zolbetuximab triplet achieves the highest mPFS (18.0 months) in first-line gastric cancer
- For pancreatic cancer specifically: IBI343 and FG-M108 are the leading candidates, with FG-M108 showing an impressive 53.1% ORR in first-line
What This Means for International Patients
1. Access to Cutting-Edge Therapies
China is home to more Claudin18.2 clinical trials than any other country. For patients with gastric, gastroesophageal junction, or pancreatic cancers that express Claudin18.2, Chinese trial sites offer:
- Earlier access to Phase II/III therapies not yet available elsewhere
- Lower trial costs compared to US/EU sites
- High-volume centers with extensive experience in these cancers
2. Molecular Testing Is Essential
Before exploring Claudin18.2 therapies, you need:
- Claudin18.2 expression testing (immunohistochemistry) — determines eligibility for most trials
- HER2 status — some trials exclude HER2-positive patients
- MSI/MMR status — may affect immunotherapy eligibility
- PD-L1 expression — relevant for combination trials
3. Current Cost Landscape
| Drug | Approximate Cost | Insurance Coverage |
|---|---|---|
| Zolbetuximab | ~¥5,978/100mg vial | ❌ Not in national insurance |
| CT041 (CAR-T) | TBD (if approved) | TBD |
| Trial participation | Usually free (drug + monitoring) | N/A |
For international patients: Clinical trial participation typically covers the study drug and key monitoring costs. Hospital fees, travel, and accommodation are patient responsibilities.
4. Trial Sites Worth Considering
| Center | City | Strengths |
|---|---|---|
| Fudan University Zhongshan Hospital | Shanghai | Gastric cancer high-volume center |
| Ruijin Hospital | Shanghai | Pancreatic cancer, multiple Claudin18.2 trials |
| Peking University Cancer Hospital | Beijing | Gastric cancer, CAR-T experience |
| Sun Yat-sen University Cancer Center | Guangzhou | Southern China hub, multiple trials |
The Bottom Line
Claudin18.2 is no longer a theoretical target — it’s a validated therapeutic marker with approved drugs and a deep pipeline. For patients with gastric or pancreatic cancers:
- Get Claudin18.2 testing done — it determines whether you’re eligible for an entire class of therapies
- Consider Chinese clinical trials — China leads the world in Claudin18.2 drug development, with multiple Phase III trials actively recruiting
- Understand the cost reality — Zolbetuximab is approved but expensive (self-pay); trial participation is typically free for the study drug
- Timing matters — For pancreatic cancer, FG-M108 (1L, ORR 53.1%) and IBI343 (2L+, Phase III) represent the most advanced options
The Claudin18.2 landscape is evolving rapidly. What’s experimental today may be standard of care within 1–2 years. Staying informed — and getting molecular testing done early — is the best strategy.
This article is based on a comprehensive analysis of Claudin18.2 targeted therapies published by 小胰宝胰腺CIC (April 2026 update). Drug statuses and clinical trial data are current as of April 28, 2026. This article does not constitute medical advice. For the latest trial availability, contact our clinical trials team.